

WORLDWIDE REGISTRATION

Dolutegravir 5 mg Dispersible Tablets

APPROVAL

Argentina	Kazakhstan	Uruguay
Australia	Kenya	United States
Botswana	Malawi	Zambia
Brazil	Mexico	Zimbabwe
Cameroon	Namibia	
Canada	Niger	
Chile	Peru	
China	Singapore	
Colombia	South Africa	
Cote d'Ivoire	Switzerland	
Democratic Republic of Congo	Tanzania	
Ecuador	Thailand	
European Union	Trinidad & Tobago	
Gabon	Uganda	
Ghana	United Kingdom	
Israel		

SUBMISSION

Algeria	Senegal
Burkina Faso	United Arab Emirates
Egypt	Ukraine
Ethiopia	Uzbekistan
Mozambique	
Nigeria	
Turkey	

- ✓ "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- ✓ "Submission" means: A registration dossier has been submitted to local authority for review in the relevant country. Please note, Submission does not guarantee that a Marketing Authorisation will be granted.
- ✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 24 November 2023 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.